Affordable Access

deepdyve-link
Publisher Website

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

Authors
  • Harris, Andrew C1
  • Young, Rachel2
  • Devine, Steven3
  • Hogan, William J4
  • Ayuk, Francis5
  • Bunworasate, Udomsak6
  • Chanswangphuwana, Chantiya6
  • Efebera, Yvonne A3
  • Holler, Ernst7
  • Litzow, Mark4
  • Ordemann, Rainer8
  • Qayed, Muna9
  • Renteria, Anne S10
  • Reshef, Ran11
  • Wölfl, Matthias12
  • Chen, Yi-Bin13
  • Goldstein, Steven14
  • Jagasia, Madan15
  • Locatelli, Franco16
  • Mielke, Stephan17
  • And 5 more
  • 1 Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan; Blood and Marrow Transplantation Program, University of Utah, Salt Lake City, Utah.
  • 2 Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan; Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
  • 3 Blood and Marrow Transplantation Program, Ohio State University, Columbus, Ohio.
  • 4 Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, Minnesota.
  • 5 Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany. , (Germany)
  • 6 Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand. , (Thailand)
  • 7 Blood and Marrow Transplantation Program, University of Regensburg, Regensburg, Germany. , (Germany)
  • 8 Blood and Marrow Transplantation Program, University Hospital TU Dresden, Dresden, Germany. , (Germany)
  • 9 Pediatric Blood and Marrow Transplantation Program, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia. , (Georgia)
  • 10 Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
  • 11 Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, New York.
  • 12 Pediatric Blood and Marrow Transplantation Program, Children's Hospital, University of Würzburg, Würzburg, Germany. , (Germany)
  • 13 Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, Massachusetts.
  • 14 Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan.
  • 15 Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • 16 Pediatric Blood and Marrow Transplantation Program, Ospedale Pediatrico Bambino Gesu, Rome, Italy. , (Italy)
  • 17 Blood and Marrow Transplantation Program, University of Würzburg, Würzburg, Germany. , (Germany)
  • 18 Blood and Marrow Transplantation Program, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 19 Pediatric Blood and Marrow Transplantation Program, The Hospital for Sick Children, Toronto, Ontario, Canada. , (Canada)
  • 20 Federal Clinical Research Center for Children's Hematology, Oncology and Immunology, Moscow, Russian Federation. , (Russia)
  • 21 Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan; Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai Hospital, New York, New York. Electronic address: [email protected]
Type
Published Article
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Publication Date
January 2016
Volume
22
Issue
1
Pages
4–10
Identifiers
DOI: 10.1016/j.bbmt.2015.09.001
PMID: 26386318
Source
Medline
Keywords
License
Unknown

Abstract

Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD varies greatly between transplant centers and is frequently not agreed on by independent reviewers. The lack of standardized approaches to handle common sources of discrepancy in GVHD grading likely contributes to why promising GVHD treatments reported from single centers have failed to show benefit in randomized multicenter clinical trials. We developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of GVHD for use in a large international GVHD research consortium. During the first year of use, the guidance followed discussion of complex clinical phenotypes by experienced transplant physicians and data managers. These guidelines increase the uniformity of GVHD symptom capture, which may improve the reproducibility of GVHD clinical trials after further prospective validation.

Report this publication

Statistics

Seen <100 times